The TRIUMPH program includes multiple phase 3 trials, and one trial, TRIUMPH-Outcomes, is specifically designed to answer the question of whether retatrutide reduces major adverse cardiovascular events
Patients are recommended to start Wegovy injectable at 0.25 mg weekly and increase the dose every 4 weeks until reaching their maintenance dose (maximum 2.4 mg)
There are some slight variations to this process on whether the assay is a direct, indirect, or sandwich ELISA with each of these assays have different advantages and disadvantages (not discussed here) but in the end they all report results the same
The However, these amounts are general estimations
As a general principle, fewer ingredients means fewer unknown interactions, so a two-peptide blend involves less combinatorial uncertainty than a four-peptide one but that is not the same as being safe. A large, separate risk is product quality: these are unregulated research chemicals, and independent testing across the market has found mislabeled, underdosed, or contaminated products
They are real and so discouraging